#NIH clinical trial of investigational vaccine for #COVID_19 begins
A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is funding the trial. KPWHRI is part of NIAID’s Infectious Diseases Clinical Research Consortium. The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks. The first participant received the investigational vaccine today. The study is evaluating different doses of the experimental vaccine for safety and its ability to induce an immune response in participants. This is the first of multiple steps in the clinical trial process for evaluating the potential benefit of the vaccine. |
SpaceX Starship ‘Lost’ After Reaching Space During Third Test Flight
875214.03.2024, 20:27Neuralink's first human patient can control mouse through thinking, says Elon Musk
442920.02.2024, 15:24A Bronze Age lip-paint from southeastern Iran (photo)
369506.02.2024, 20:24Apple thinks iOS 18 might be the ‘biggest’ iOS update ever
207803.02.2024, 20:06Elon Musk's Neuralink implants brain chip in first human (video)
372130.01.2024, 10:30Nokia smartphone brand will soon disappear: Why has it failed to gain a place in the market?
521118.01.2024, 23:48